Saw Palmetto

Evidence Fact Sheet

Serenoa repens

Saw palmetto (Serenoa repens) is a lipophilic berry extract studied for lower-urinary-tract / prostate and androgen-pathway (5-alpha-reductase / DHT) research contexts. High-certainty Cochrane evidence and the rigorous CAMUS RCT found whole-extract gives little-to-no benefit over placebo for BPH symptoms; a hexanic-extract meta-analysis is more favorable. Legal DSHEA/EU/ANVISA supplement; no authorized health claim.

Also known as: Saw Palmetto · Serenoa repens · Sabal serrulata · Saw palmetto berry extract

Overview

Saw palmetto is a standardized lipophilic extract of the Serenoa repens berry (typically 85-95% fatty acids and sterols), one of the best-selling prostate-category botanicals. Its proposed mechanisms in research are inhibition of 5-alpha-reductase (reducing testosterone-to-DHT conversion), anti-androgenic and anti-inflammatory effects on prostatic tissue, and alpha-1 adrenoceptor modulation relevant to lower-urinary-tract smooth muscle. RCT and commercial doses cluster at 320 mg/day of standardized extract (1x320 mg or 2x160 mg with food). It is a legal dietary-supplement ingredient under US DSHEA, marketable as a food supplement in the EU (with an EMA traditional-herbal monograph) and under Brazil's ANVISA; China has no clear market-access pathway. No regulator has authorized a health claim, and disease claims (treating BPH or hair loss, or replacing finasteride) are prohibited. This page reports research findings, not medical advice.

Mechanism of Action

5-alpha-reductase inhibition (reduces DHT conversion · research context) · Anti-androgenic activity on prostate tissue (preclinical/biomarker research) · Anti-inflammatory and anti-edematous effects on prostatic tissue (research-stage) · Alpha-1 adrenoceptor modulation relevant to lower-urinary-tract smooth muscle (mechanistic research)

Body systems: HORMONE · URINARY

Evidence-Based Benefits

Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Saw Palmetto is not characterized as a treatment for any disease.

Lower-Urinary-Tract / BPH Symptoms (Whole Extract vs Placebo)

Null / no benefit Meta-analysis supported

The 2023 Cochrane systematic review—the highest-tier evidence on this question—pooled 27 studies and concluded that Serenoa repens alone provides little to no benefit for men with lower urinary tract symptoms due to benign prostatic enlargement. The short-term IPSS difference versus placebo (-0.90 points) is below the threshold usually considered clinically meaningful, and the certainty of evidence was rated high. This is an honest negative for the whole-extract / general saw palmetto framing.

Effect size: not quantified on this page — see the linked study below for the reported figures.

Source: PMID 37345871 · Franco 2023 · Cochrane Database Syst Rev

Lower-Urinary-Tract Symptoms — Large Rigorous RCT (CAMUS)

Null / no benefit RCT supported

369 menrandomized · age >=45
0.79 points favoring placeboAUASI group difference
320 mg/d (up to 3x)escalating dose · 72 wk

The NIH-funded CAMUS trial randomized 369 men to escalating doses of saw palmetto extract (320 mg/d up to triple) versus placebo over 72 weeks. Symptom scores improved similarly in both arms, and the group difference of 0.79 points actually favored placebo. The authors concluded that increasing doses did not reduce lower urinary tract symptoms more than placebo—a prominent honest negative from the most rigorous single trial.

Reported effect: Saw palmetto AUASI -2.20 (95% CI -3.04 to -1.36) vs placebo -2.99 (95% CI -3.81 to -2.17); group mean difference 0.79 points favoring placebo; n=369

“Among the 369 men aged 45 years or older... mean AUASI scores decreased from 14.42 to 12.22 points (-2.20 points; 95% CI, -3.04 to -1.36) with saw palmetto extract and from 14.69 to 11.70 points (-2.99 points; 95% CI, -3.81 to -2.17) with placebo. The group mean difference in AUASI score change from baseline to 72 weeks between the saw palmetto extract and placebo groups was 0.79 points favoring placebo... Increasing doses of a saw palmetto fruit extract did not reduce lower urinary tract symptoms more than placebo.”

Source: PMID 21954478 · Barry 2011 · JAMA

Lower-Urinary-Tract Symptoms — Hexanic Extract (Permixon)

Meta-analysis supported

-0.64 voids/night (95% CI -0.98 to -0.31)nocturia vs placebo · P<0.001
+2.75 mL/s (95% CI 0.57 to 4.93)Qmax vs placebo · P=0.01
-5.73 IPSS (95% CI -6.91 to -4.54)IPSS from baseline · P<0.001

Evidence for the specific hexanic extract of Serenoa repens (Permixon) is more favorable than for saw palmetto in general. A 2018 meta-analysis reported reduced nocturia (-0.64 voids/night vs placebo) and improved peak urinary flow (Qmax +2.75 mL/s vs placebo), with an IPSS improvement from baseline of -5.73 points and tolerability comparable to alpha-blockers. The contrast with the Cochrane/CAMUS null findings highlights that extract type and preparation matter—results for one branded extract do not generalize to all saw palmetto products.

Reported effect: Nocturia -0.64 voids/night (95% CI -0.98 to -0.31, P<0.001); Qmax +2.75 mL/s (95% CI 0.57 to 4.93, P=0.01); IPSS from baseline -5.73 (95% CI -6.91 to -4.54, P<0.001)

“Hexanic extract of Serenoa repens (HESr; Permixon) ... reduced nocturia ... by 0.64 (95% CI -0.98 to -0.31) fewer voids/night (P < 0.001) ... and there was an additional mean increase in Qmax of 2.75 mL/s (95% CI 0.57 to 4.93; P = 0.01) ... mean improvement in IPSS from baseline of -5.73 points (95% CI -6.91 to -4.54; P < 0.001).”

Source: PMID 29694707 · Vela-Navarrete 2018 · BJU Int

Androgenetic Alopecia / Hair Loss

Emerging / indexed

5 RCTs + 2 cohortsstudies reviewed
60% / 27%hair-quality / haircount improvement
100-320 mgSP dose range studied

A 2020 systematic review of saw palmetto for hair loss summarized five RCTs and two prospective cohorts using topical or oral SP supplements (100-320 mg). Reported figures included 60% improvement in overall hair quality, 27% improvement in total haircount, increased hair density in 83.3% of patients, and stabilized progression in 52%. The authors stressed that robust high-quality data are lacking and that SP's sole contribution is unclear because most products were combinations—so this is suggestive, not established. SP must not be presented as a treatment for hair loss.

Reported effect: 5 RCTs + 2 prospective cohorts; SP 100-320 mg; 60% improvement in overall hair quality, 27% improvement in total haircount, increased hair density in 83.3%, stabilized progression in 52%

“Five randomized clinical trials (RCTs) and 2 prospective cohort studies demonstrated positive effects of topical and oral supplements containing SP (100-320 mg) among patients with androgenetic alopecia (AGA) and telogen effluvium. Sixty percent improvement in overall hair quality, 27% improvement in total haircount, increased hair density in 83.3% of patients, and stabilized disease progression among 52% were noted... Although robust high-quality data are lacking, supplements containing SP may be a treatment option for patients with AGA, telogen effluvium, and self-perceived hair thinning.”

Source: PMID 33313047 · Evron 2020 · Skin Appendage Disord

Dosage (research context · not a recommendation)

Commercial/RCT doses 320 mg/day standardized lipophilic extract (85-95% fatty acids/sterols), usually 1x320 mg or 2x160 mg with food. Educational reference, not a dosing recommendation.

Regulatory Status · 4 Markets

US · FDA: Legal DSHEA dietary-supplement ingredient; prostate-health category bestseller (~320 mg/day). Structure/function claims with FDA disclaimer permitted; disease claims (treats BPH / treats hair loss / replaces finasteride) prohibited. No FDA-authorized health claim.
EU · EFSA: Marketable as food supplement (Directive 2002/46/EC) in several member states; EMA has a traditional-herbal monograph (BPH well-established use) and Permixon is registered as a medicine in some member states. EFSA has authorized no health claim.
CN · China: China SAMR: not listed in health-food raw-material catalogue or medicine-food homology list; no clear market-access pathway; market entry restricted.
BR · ANVISA: Legal food supplement under ANVISA RDC 243/2018 + IN 28/2018 (Serenoa repens extract permitted); daily-amount and use-warning labeling required. No IN 28/2018 Anexo V authorized functional claim.

Safety

Anti-androgenic activity: not recommended in pregnancy, breastfeeding, or children (theoretical anti-androgenic / feminization concern for a male fetus); women who are or may become pregnant should consult a clinician before use. Per NCCIH, saw palmetto does not appear to meaningfully alter PSA readings, but disclose any supplement use to your physician before prostate screening. Generally well tolerated; mild GI upset most common. Cochrane evidence is inconsistent and the rigorous STEP/CAMUS trial did not meet its primary endpoint, so BPH framing must stay conservative. Must NOT claim equivalence/superiority to finasteride or that it treats hair loss / BPH. This describes scientific evidence, not medical advice.

Goals: reproductive-health

Lifestyles: senior-60-plus

References

PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.

PMID 37345871 · Franco 2023 · Cochrane Database Syst Rev — Lower-Urinary-Tract / BPH Symptoms (Whole Extract vs Placebo)
PMID 21954478 · Barry 2011 · JAMA — Lower-Urinary-Tract Symptoms — Large Rigorous RCT (CAMUS)
PMID 29694707 · Vela-Navarrete 2018 · BJU Int — Lower-Urinary-Tract Symptoms — Hexanic Extract (Permixon)
PMID 33313047 · Evron 2020 · Skin Appendage Disord — Androgenetic Alopecia / Hair Loss

Frequently Asked Questions

1. Why do some studies show a benefit and others show none?

Extract type and standardization differ between products. The Cochrane review and CAMUS trial—covering general/whole saw palmetto extracts—found no meaningful benefit over placebo, while the 2018 meta-analysis of the hexanic extract (Permixon) reported reduced nocturia (-0.64 voids/night) and improved peak flow (Qmax +2.75 mL/s). Findings for one branded extract do not generalize to all saw palmetto supplements.

2. Can saw palmetto help with hair loss?

Evidence is preliminary. A 2020 systematic review summarized five RCTs and two cohorts and reported figures such as 60% improvement in overall hair quality and 27% improvement in total haircount, but the authors emphasized that high-quality data are lacking and that saw palmetto's sole contribution is unclear because most products were combinations. This is research-stage and saw palmetto must not be presented as a hair-loss treatment.

3. Is saw palmetto a regulated supplement, and is it safe?

It is a legal dietary-supplement ingredient under US DSHEA, an EU food supplement (with an EMA traditional-herbal monograph), and a permitted ANVISA supplement in Brazil; China has no clear market-access pathway, and no regulator has authorized a health claim. It is generally well tolerated, with mild GI upset most common. Because of anti-androgenic activity it is not recommended in pregnancy, breastfeeding, or children, and any supplement use should be disclosed before prostate screening. This is evidence reporting, not medical advice or a dosing recommendation.

Last evidence review: 2026-06-22

← Evidence library